The clinical trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China and aims to evaluate the safety and preliminary efficacy of universal allogeneic CAR T-cell therapy targeting CD19 and BCMA in patients with relapse/refractory autoimmune diseases. The market for CAR T-cell therapies is expanding, particularly in the context of autoimmune diseases, where current treatment options are limited and often ineffective. The trial's focus on multiple autoimmune conditions, including systemic lupus erythematosus and systemic sclerosis, positions it strategically within a niche but growing segment of the biopharma market. Competitive implications include potential differentiation from existing therapies through the use of allogeneic cells, which may offer advantages in terms of accessibility and scalability. Diligence considerations should include the regulatory landscape in China and potential pathways for global expansion.